ATAI Life Sciences/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Ticker
$ATAI
Sector
Primary listing
Employees
-
Headquarters
Website
ATAI Metrics
BasicAdvanced
$1.2B
-
-$0.69
1.56
-
Price and volume
Market cap
$1.2B
Beta
1.56
52-week high
$5.97
52-week low
$1.03
Average daily volume
5.8M
Financial strength
Current ratio
4.019
Quick ratio
3.807
Long term debt to equity
3.927
Total debt to equity
8.511
Interest coverage (TTM)
-22.29%
Profitability
EBITDA (TTM)
-94.849
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,171.24%
Operating margin (TTM)
-4,140.32%
Effective tax rate (TTM)
0.58%
Management effectiveness
Return on assets (TTM)
-29.51%
Return on equity (TTM)
-76.50%
Valuation
Price to revenue (TTM)
411.216
Price to book
8.08
Price to tangible book (TTM)
8.28
Price to free cash flow (TTM)
-12.362
Free cash flow yield (TTM)
-8.09%
Free cash flow per share (TTM)
-0.442
Growth
Revenue change (TTM)
510.85%
Earnings per share change (TTM)
90.44%
3-year revenue growth (CAGR)
51.35%
3-year earnings per share growth (CAGR)
-18.51%
What the Analysts think about ATAI
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
Bulls say / Bears say
A Phase 2b trial with 193 patients showed that a single intranasal dose of BPL-003 produced rapid, strong, and lasting antidepressant effects, achieving all main and key secondary endpoints. This positions the drug for accelerated Phase 3 development and possible regulatory discussions within interventional psychiatry care models (FT).
ATAI secured strategic control of BPL-003’s patent-protected formulation with a $390 million all-share acquisition of Beckley Psytech, highlighting investor confidence in ATAI’s leadership in psychedelic-based mental health therapies (FT).
BPL-003’s intranasal administration allowed more than 90 percent of patients to be ready for discharge within 90 minutes after dosing, cutting down on in-clinic supervision needs and improving accessibility and cost-efficiency of the treatment (FT).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
ATAI Financial Performance
Revenues and expenses
ATAI Earnings Performance
Company profitability
ATAI News
AllArticlesVideos
atai Life Sciences' Glenn Short discusses the company's NIH grant and innovative discovery program – ICYMI
Proactive Investors4 days ago
Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients
Benzinga2 weeks ago
atai shares jump 10% on positive trial data for depression nasal spray
Proactive Investors2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $1.2B as of October 07, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of October 07, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.